End-of-day quote
Swiss Exchange
06:00:00 2024-04-24 pm EDT
|
5-day change
|
1st Jan Change
|
1.25
CHF
|
-6.72%
|
|
-4.58%
|
-37.19%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
20.24
|
10.86
|
2.114
|
873.4
|
274.3
|
132
|
Enterprise Value (EV)
1 |
21.12
|
11.65
|
3.724
|
836
|
233.8
|
117.1
|
P/E ratio
|
-6.89
x
|
-24.5
x
|
-0.28
x
|
-82.9
x
|
-6.44
x
|
-2.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
19,225,462
x
|
-
|
-
|
82,606,200
x
|
21,700,294
x
|
EV / Revenue
|
-
|
20,620,152
x
|
-
|
-
|
70,411,981
x
|
19,251,190
x
|
EV / EBITDA
|
-12.2
x
|
-24.1
x
|
-3.94
x
|
-43.2
x
|
-7.22
x
|
-3.69
x
|
EV / FCF
|
-33.9
x
|
-21.8
x
|
-6.83
x
|
-56.2
x
|
-10.9
x
|
-6.11
x
|
FCF Yield
|
-2.95%
|
-4.59%
|
-14.7%
|
-1.78%
|
-9.15%
|
-16.4%
|
Price to Book
|
0.96
x
|
0.51
x
|
0.15
x
|
13
x
|
1.41
x
|
0.91
x
|
Nbr of stocks (in thousands)
|
5,060
|
5,222
|
5,285
|
8,117
|
11,026
|
10,997
|
Reference price
2 |
4.000
|
2.080
|
0.4000
|
107.6
|
24.88
|
12.00
|
Announcement Date
|
4/30/18
|
4/30/19
|
4/30/20
|
4/15/21
|
4/1/22
|
4/14/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
0.565
|
-
|
-
|
3.321
|
6.081
|
EBITDA
1 |
-1.733
|
-0.483
|
-0.946
|
-19.36
|
-32.38
|
-31.74
|
EBIT
1 |
-1.736
|
-0.5
|
-0.947
|
-19.36
|
-34.24
|
-35.21
|
Operating Margin
|
-
|
-88.5%
|
-
|
-
|
-1,030.89%
|
-578.98%
|
Earnings before Tax (EBT)
1 |
-1.901
|
-0.416
|
-12.16
|
-6.261
|
-35.52
|
-54.32
|
Net income
1 |
-2.887
|
-0.436
|
-7.46
|
-7.828
|
-34.7
|
-50.79
|
Net margin
|
-
|
-77.17%
|
-
|
-
|
-1,045.02%
|
-835.22%
|
EPS
2 |
-0.5809
|
-0.0851
|
-1.418
|
-1.298
|
-3.864
|
-4.805
|
Free Cash Flow
1 |
-0.623
|
-0.535
|
-0.5456
|
-14.87
|
-21.39
|
-19.15
|
FCF margin
|
-
|
-94.69%
|
-
|
-
|
-644.23%
|
-314.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/18
|
4/30/19
|
4/30/20
|
4/15/21
|
4/1/22
|
4/14/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
0.88
|
0.79
|
1.61
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
37.4
|
40.5
|
14.9
|
Leverage (Debt/EBITDA)
|
-0.5061
x
|
-1.631
x
|
-1.702
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-0.62
|
-0.54
|
-0.55
|
-14.9
|
-21.4
|
-19.2
|
ROE (net income / shareholders' equity)
|
-13.4%
|
-2.06%
|
-41.9%
|
-19.2%
|
-27.9%
|
-31.1%
|
ROA (Net income/ Total Assets)
|
-3.48%
|
-0.94%
|
-2.14%
|
-24.7%
|
-13%
|
-9.99%
|
Assets
1 |
83.01
|
46.43
|
349.4
|
31.67
|
267.3
|
508.3
|
Book Value Per Share
2 |
4.180
|
4.080
|
2.710
|
8.260
|
17.70
|
13.20
|
Cash Flow per Share
2 |
0.0300
|
0.0500
|
0.0200
|
4.690
|
4.350
|
1.750
|
Capex
|
-
|
-
|
-
|
-
|
-
|
0.03
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
0.54%
|
Announcement Date
|
4/30/18
|
4/30/19
|
4/30/20
|
4/15/21
|
4/1/22
|
4/14/23
|
|
1st Jan change
|
Capi.
|
---|
| -37.19% | 17.82M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|